EQS-Ad-hoc: SCHOTT Pharma AG & Co. KGaA / Key word(s): Quarterly / Interim Statement/Quarter Results SCHOTT Pharma: Preliminary Q2 2025 figures exceed capital market expectations Based on preliminary figures, SCHOTT Pharma expects an increase in sales, EBITDA and EBITDA margin in the second quarter of 2025 (as of March 31, 2025). The company expects Q2 2025 revenues of EUR 252m, corresponding to a year-over-year growth of 10% at constant currencies. Accordingly, SCHOTT Pharma expects an EBITDA of EUR 72m and a corresponding EBITDA margin of 28.6%. These figures exceed the current market consensus of EUR 242m for revenues, 4% growth at constant currencies, EUR 62m EBITDA and a 25.5% EBITDA margin (source: Vara Research). SCHOTT Pharma maintains its full-year guidance for the fiscal year 2025 as published in December 2024. The company will publish its detailed figures for the second quarter and first half of 2025 on May 15, 2025. Investor contact Press contact End of Inside Information
10-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | SCHOTT Pharma AG & Co. KGaA |
Hattenbergstraße 10 | |
55122 Mainz | |
Germany | |
ISIN: | DE000A3ENQ51 |
WKN: | A3ENQ5 |
Indices: | SDAX |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; Vienna Stock Exchange |
EQS News ID: | 2115610 |
End of Announcement | EQS News Service |
|
2115610 10-Apr-2025 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.